TRIM33 Antibody

1. Tumors from paraneoplastic anti-TIF1gamma-positive cancer-associated myositis patients showed an increased number of genetic alterations, such as mutations and loss of heterozygosity, in TIF1 genes. PMID: 29149307
2. Data show that tripartite motif-containing protein 33 (TRIM33) silencing attenuates down-regulation of MYC and TGF-beta signaling in response to bromodomain and extraterminal domain protein inhibitors (BETi). PMID: 27432991
3. suggest that SnoN suppresses TGF-betainduced epithelial-mesenchymal transition and invasion of bladder cancer cells in a TIF1gammadependent manner PMID: 27430247
4. The adenovirus E4-ORF3 protein functions as a SUMO E3 ligase for TIF-1gamma sumoylation and poly-SUMO chain elongation. PMID: 27247387
5. our findings reveal a new mechanism by which SOX2-mediated transcription repression of TIF1gamma promotes TGF-beta-induced epithelial-mesenchymal transition in non-small-cell lung cancer PMID: 25961934
6. our work indicates that TIF1gamma exerts its tumor-suppressive functions in part by promoting chromosomal stability. PMID: 26282171
7. Results show that TRIM33 is significantly downregulated in clear renal cell carcinoma tissues which seems to correlate with pathologic stages and grades. PMID: 25381221
8. Tumour suppressor TRIM33 targets nuclear beta-catenin degradation PMID: 25639486
9. Study suggests TRIM33 and NRAS-CSDE1 as candidate genes for autism, and may provide a novel insight into the etiology of autism PMID: 24189344
10. The dermatomyositis autoantigen TIF1gamma is markedly up-regulated during muscle regeneration in human and mouse muscle cells. PMID: 25186009
11. Data indicate that tripartite motif containing 33 protein TIF1gamma promotes sumoylation of SKI-like proto-oncogene protein SnoN1 and regulates epithelial-mesenchymal transition (EMT). PMID: 25059663
12. regulates tumor growth and metastasis through inhibition of TGF-beta/Smad signaling and may serve as a novel prognostic biomarker in hepatocellular carcinoma PMID: 24954480
13. The ubiquitination of DHX33 by TRIM33 is lysine 63 specific and is required for the formation of the DHX33-NLRP3 inflammasome complex. PMID: 25172487
14. Results identify a new TGFbeta regulatory layer, whereby sumoylation strengthens the TIF1gamma repressive action on canonical TGFbeta signaling. PMID: 23788427
15. Case Report: suggest that TIF1gamma expression in neoplasms not only determines the tumour activity but also causes dermatomyositis. PMID: 23407650
16. mutation and methylation in the promoter region of TIF1gamma in non-small cell lung cancer PMID: 23676978
17. TRIM33 plays a role in PARP-dependent DNA damage response and regulates ALC1 activity by promoting its timely removal from sites of DNA damage. PMID: 23926104
18. These studies demonstrate that anti-NXP-2 and anti-TIF-1gamma antibodies are frequent DM specificities (found in 55% of patients) and are present in most patients with cancer-associated dermatomyositis. PMID: 24037894
19. TIF1gamma is an APC/C-interacting protein that regulates APC/C function. It is not a substrate for APC/C-dependent ubiquitylation but associates specifically with the APC/C holoenzyme & Cdc20 to affect APC/C activity & progression through mitosis. PMID: 23160376
20. Tif1gamma transgene is essential for the terminal differentiation of mammary alveolar epithelial cells at the end of pregnancy and to ensure lactation. PMID: 23154409
21. Data suggest that the formation of transient TIF1gamma-Smad2-Smad4 ternary complexes is the only one that can account for TGF-beta signaling. PMID: 22461896
22. Adenovirus E4orf3 targets TIF1 gamma for proteasome-dependent degradation during infection. PMID: 22205733
23. These results suggest that E4-ORF3 targets proteins for relocalization through a loosely homologous sequence dependent on accessibility. PMID: 22123502
24. Study reports an essential role for TRIM33 in the activation of Gsc and Mixl1 by nodal signals, and delineate how Smads gain access to poised promoters of master regulators under the command of nodal TGF-beta signals. PMID: 22196728
25. Data suggest that over-expression of TIF1gamma occurs in early stages of colorectal carcinogenesis, is inversely related with Smad4 loss, and may be a prognostic indicator for poor outcome. PMID: 22046087
26. TIF1gamma binds to and represses the plasminogen activator inhibitor 1 promoter, demonstrating a direct role of TIF1gamma in TGF-beta-dependent gene expression PMID: 21597466
27. TIF1gamma dictates the residence time of activated Smad complexes at promoters of TGF-beta superfamily target genes. PMID: 21726812
28. TIF1gamma was almost undetectable in leukemic cells of 35% of CMML patients. This downregulation was related to the hypermethylation of CpG sequences and specific histone modifications in the gene promoter. PMID: 21537084
29. regulation of adult hematopoiesis through TIF1gamma-mediated transcriptional repression of TAL1 and PU.1 target genes. PMID: 21474105
30. Hyperthermia incurred platelet glycoprotein Ibalpha ectodomain shedding. PMID: 20158380
31. Chromatin immunoprecipitation assays in human CD34(+) cells supported a TIF1gamma-dependent recruitment of positive elongation factors to erythroid genes to promote transcription elongation by counteracting Pol II pausing. PMID: 20603019
32. These studies are consistent with a model in which TIF1gamma acts to ubiquitinate LDB1 leading to degradation of LDB1 and changes in transcription of LDB1-dependent promoters. PMID: 20447379
33. TIF1alpha interacts with TIF1gamma and the coiled-coil region of TIF1gamma is necessary for this interaction. PMID: 12096914
34. Thus, Smad2/3-TIF1gamma and Smad2/3-Smad4 function as complementary effector arms in the control of hematopoietic cell fate by the TGFbeta/Smad pathway. PMID: 16751102
35. Study reports that TIF1gamma expression is markedly down-regulated in human pancreatic tumors by quantitative RT-PCR and immunohistochemistry. PMID: 19629168

Show More

Hide All

HGNC: 16290

OMIM: 605769

KEGG: hsa:51592

STRING: 9606.ENSP00000351250

UniGene: Hs.26837